norfenfluramine has been researched along with dexfenfluramine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Cespedes, AT; McMullen, MR; Patel, A; Roth, JD; Rowland, NE | 1 |
| Jagroop, IA; Mikhailidis, DP | 1 |
| Cohen, AF; Gijsman, HJ; Hessing, TJ; Pennings, EJ; Pieters, MS; Schoemaker, RC; van Gerven, JM; Verkes, RJ | 1 |
| Hong, F; Hong, Z; Nelson, DP; Olschewski, A; Reeve, HL; Weir, EK | 1 |
| Dempsie, Y; Loughlin, L; MacLean, MR; MacRitchie, NA; Mair, KM; Morecroft, I; Nilsen, M; White, K; Wright, AF | 1 |
1 trial(s) available for norfenfluramine and dexfenfluramine
| Article | Year |
|---|---|
Saccadic peak velocity and EEG as end-points for a serotonergic challenge test.
Topics: Adolescent; Adult; Cross-Over Studies; Dexfenfluramine; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Norfenfluramine; Saccades; Serotonin; Serotonin Receptor Agonists; Substance-Related Disorders | 2002 |
5 other study(ies) available for norfenfluramine and dexfenfluramine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Dexfenfluramine and norfenfluramine: comparison of mechanism of action in feeding and brain Fos-ir studies.
Topics: 5,7-Dihydroxytryptamine; Animals; Anorexia; Behavior, Animal; Brain; Dexfenfluramine; Eating; Female; Fenclonine; Immunohistochemistry; Male; Norfenfluramine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2000 |
An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models.
Topics: Adult; Appetite Depressants; Blood Platelets; Cell Size; Dexfenfluramine; Dose-Response Relationship, Drug; Female; Fenfluramine; Humans; Male; Middle Aged; Models, Biological; Neurons; Norfenfluramine; Phenethylamines; Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2000 |
Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine.
Topics: Animals; Calcium; Dexfenfluramine; In Vitro Techniques; Lung; Male; Membrane Potentials; Norfenfluramine; Patch-Clamp Techniques; Perfusion; Potassium Channels; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT2; Sarcoplasmic Reticulum; Serotonin Agents; Serotonin Receptor Agonists; Vasoconstriction | 2004 |
Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Aryl Hydrocarbon Hydroxylases; Cell Proliferation; Cells, Cultured; Cytochrome P-450 CYP1B1; Dexfenfluramine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Familial Primary Pulmonary Hypertension; Female; Hypertension, Pulmonary; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Norfenfluramine; Ovariectomy; Pulmonary Artery; Serotonin; Sex Factors; Tryptophan Hydroxylase; Ventricular Function, Right; Ventricular Pressure | 2013 |